NasdaqGS - Nasdaq Real Time Price USD

Scholar Rock Holding Corporation (SRRK)

30.55

-0.28

(-0.91%)

At close: May 16 at 4:00:01 PM EDT

30.17

-0.38

(-1.24%)

After hours: May 16 at 7:02:36 PM EDT

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., May 16, 2025--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 105,700 shares of its common stock to 14 newly hired employees, consisting of inducement stock options to purchase an aggregate of 60,

Business Wire 17 hours ago

SRRK
-0.91%
Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings Call Highlights: Strong Progress and ...

Scholar Rock Holding Corp (SRRK) reports significant advancements in SMA treatment and prepares for a potential US commercial launch amid financial stability and strategic global expansion.

GuruFocus.com 2 days ago

SRRK
-0.91%
Q1 2025 Scholar Rock Holding Corp Earnings Call

Q1 2025 Scholar Rock Holding Corp Earnings Call

Thomson Reuters StreetEvents 2 days ago

SRRK
-0.91%
Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass., May 14, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today reported financial results and updates for the first quarter ended March 31, 2025.

Business Wire 3 days ago

SRRK
-0.91%
Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

CAMBRIDGE, Mass., May 07, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that management will host a conference call to discuss its first quarter 2025 financial results and provide a business update on Wednesday, May 14, 2025, at 8:15am ET.

Business Wire 10 days ago

SRRK
-0.91%
US High Growth Tech Stocks To Watch

The United States market has shown a positive trend, with a 2.8% increase over the last week and a 9.3% rise over the past year, while earnings are projected to grow by 14% annually in the coming years. In this environment, identifying high growth tech stocks requires focusing on companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable market dynamics.

Simply Wall St. 12 days ago

EEX

SRRK
-0.91%

CORZ
Why Scholar Rock Stock Took a Knock on Monday

Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board.

Motley Fool 18 days ago

SRRK
-0.91%
Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth

CAMBRIDGE, Mass., April 28, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, announced today that David Hallal has been appointed Chief Executive Officer succeeding Jay Backstrom, M.D. David Hallal has served as Chairman of the Board at Scholar Rock since 2017 and just prior to that spent more than a decade as CEO, COO, and CCO of Alexion building

Business Wire 19 days ago

SRRK
-0.91%
Why Scholar Rock Holding Stock Topped the Market Today

Biotech stock Scholar Rock (NASDAQ: SRRK) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds. Scholar Rock targets relatively uncommon disorders that might lack effective treatments. Its current lead drug candidate -- apitegromab, a medicine that preserves muscle mass in patients with two types of spinal muscular atrophy (SMA) -- is under review for approval by both the U.S. Food and Drug Administration and the European Union's European Medicines Agency (EMA).

Motley Fool 23 days ago

SRRK
-0.91%
Scholar Rock Holding Corp (SRRK) Q4 2024 Earnings Call Highlights: Clinical Success and ...

Scholar Rock Holding Corp (SRRK) reports promising clinical results and strategic preparations for the launch of apitegromab, while navigating regulatory and competitive landscapes.

GuruFocus.com 25 days ago

SRRK
-0.91%
Exploring 3 High Growth Tech Stocks In The US Market

In the last week, the United States market has been flat, but over the past 12 months, it has risen by 8.4%, with earnings expected to grow by 14% per annum in the coming years. In this environment, identifying high-growth tech stocks can be crucial for investors seeking to capitalize on potential opportunities within a dynamic sector poised for expansion.

Simply Wall St. last month

AVPT

AVPTW

SRRK
-0.91%
FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

CAMBRIDGE, Mass., March 25, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for p

Business Wire last month

SRRK
-0.91%
Scholar Rock SMA drug shows muscle function benefit

Scholar Rock’s stock is due to drop by 7.49% following the news, according to pre-market estimates.

Clinical Trials Arena last month

SRRK
-0.91%

GLDAF
Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

CAMBRIDGE, Mass., March 16, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial (NCT05156320) will be presented in multiple clinical presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Sc

Business Wire last month

SRRK
-0.91%
When Can We Expect A Profit From Scholar Rock Holding Corporation (NASDAQ:SRRK)?

Scholar Rock Holding Corporation ( NASDAQ:SRRK ) is possibly approaching a major achievement in its business, so we...

Simply Wall St. 2 months ago

SRRK
-0.91%
Q4 2024 Scholar Rock Holding Corp Earnings Call

Q4 2024 Scholar Rock Holding Corp Earnings Call

Thomson Reuters StreetEvents 2 months ago

SRRK
-0.91%
Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass., February 27, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2024.

Business Wire 2 months ago

SRRK
-0.91%
Scholar Rock to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., February 25, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences:

Business Wire 2 months ago

SRRK
-0.91%
Is Scholar Rock Holding (SRRK) One of the Oversold Biotech Stocks to Buy Now?

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against other oversold biotech stocks to buy now. Biotech Sector Performance and Challenges in 2024: Biotechnology stocks are among the most volatile in the […]

Insider Monkey 2 months ago

SRRK
-0.91%
Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

CAMBRIDGE, Mass., February 21, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that it will present additional data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 16

Business Wire 2 months ago

SRRK
-0.91%

Performance Overview

Return	SRRK	S&P 500 (^GSPC)
YTD	-29.32%	+1.30%
1-Year	+113.34%	+12.48%
3-Year	+486.37%	+48.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Scholar Rock Holding Corporation (SRRK)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings Call Highlights: Strong Progress and ...

Q1 2025 Scholar Rock Holding Corp Earnings Call

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

US High Growth Tech Stocks To Watch

Why Scholar Rock Stock Took a Knock on Monday

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth

Why Scholar Rock Holding Stock Topped the Market Today

Scholar Rock Holding Corp (SRRK) Q4 2024 Earnings Call Highlights: Clinical Success and ...

Exploring 3 High Growth Tech Stocks In The US Market

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Scholar Rock SMA drug shows muscle function benefit

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

When Can We Expect A Profit From Scholar Rock Holding Corporation (NASDAQ:SRRK)?

Q4 2024 Scholar Rock Holding Corp Earnings Call

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Scholar Rock to Participate in Upcoming Investor Conferences

Is Scholar Rock Holding (SRRK) One of the Oversold Biotech Stocks to Buy Now?

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Performance Overview